Number of patients | 111 | ||
Age (yrs) | 42.2 ± 10.3 | ||
Gender (male) (n, %) | 78 (70) | ||
Duration of symptoms (yrs) | 16 (1 to 49) | ||
Time since diagnosis (yrs) | 9 (0 to 37) | ||
HLA-B27+ (n, %) | 88 (81) | ||
History of IBD (n, %) | 11 (10) | ||
History of uveitis (n, %) | 31 (28) | ||
History of psoriasis (n, %) | 9 (8) | ||
Peripheral arthritis (n, %) | 21 (19) | ||
Current NSAID use (n, %) | 98 (88) | ||
Current DMARD use (n, %) | 26 (23) | ||
BASDAI (range 0 to 10) | 6.1 ± 1.7 | BASDAI ≥ 4 (n, %) | 98 (88) |
ASDASCRP | 3.8 ± 0.8 | ASDASCRP ≥ 2.1 (n, %) | 105 (96) |
Physician's GDA (range 0 to 10) | 5 (1 to 9) | ||
Patient's GDA (range 0 to 10) | 7 (1 to 10) | ||
ESR (mm/h) | 22 (2 to 90) | Increased ESR (n, %) | 86 (78) |
CRP (mg/l) | 15 (2 to 99) | Increased CRP (n, %) | 84 (76) |
BASFI (range 0 to 10) | 6.1 ± 2.0 | ||
Chest expansion (cm) | 3.0 (0.5 to 10.0) | ||
Modified Schober test (cm) | 2.9 (0.1 to 7.0) | ||
Occiput to wall distance (cm) | 5.0 (0.0 to 28.0) | ||
Lateral lumbar flexion L (cm) | 8.7 ± 4.1 | ||
Lateral lumbar flexion R (cm) | 8.4 ± 4.3 | ||
ASQoL (range 0 to 18) | 10 ± 4 | ||
BALP (U/L) | 17.2 (1.6 to 36.5) | ||
BALP Z-score | 0.28 (-2.59 to 5.16) | ||
PINP (μg/l) | 45.6 (16.0 to 98.0) | ||
PINP Z-score | 0.35 (-1.75 to 3.63) | ||
sCTX (pg/ml) | 206.0 (13.4-657.1) | ||
sCTX Z-score | -0.34 (-2.58 to 4.01) | ||
LS BMD T-score | -0.58 ± 1.41 | Osteopenia LS (n, %) | 34 (34) |
Osteoporosis LS (n, %) | 9 (9) | ||
LS BMD Z-score | LS Z-score ≤ -2.0 (n, %) | 9 (9) | |
Hip BMD T-score | -0.53 ± 1.12 | Osteopenia hip (n, %) | 38 (37) |
Osteoporosis hip (n, %) | 2 (2) | ||
Hip BMD Z-score | Hip Z-score ≤ -2.0 (n, %) | 4 (4) |